Document:

Exhibit 10.4

 

AUGMEDIX, INC.

1161
mission street, suite 210

san
francisco, ca 94103

 

march
07, 2019

 

Sandy Breber

Via email to: [*]

 

Dear Sandy,

 

Augmedix, Inc. (the “Company”) is pleased
to offer you employment on the following terms:

 

		1.	Position and Start Date. Beginning March 25, 2019,
you will serve in a full-time capacity as Chief Operating Officer. By signing this letter agreement, you represent and warrant
to the Company that you are under no contractual commitments inconsistent with your obligations to the Company.

 

		2.	Salary. You will be paid a salary at the initial
annual rate of $275,000, payable in Bi-weekly installments in accordance with the Company’s standard payroll practices for salaried
employees. This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time
to time.

 

		3.	Stock Options. Subject to the approval of the
Company’s Board of Directors or its Compensation Committee, you will be granted an option to purchase 275,000 shares of the Company’s
Common Stock. The exercise price per share will be equal to the fair market value per share on the date the option is granted
or on your first day of employment, whichever is later. The option will be subject to the terms and conditions applicable to options
granted under the Company’s Employee Stock Plan. You will vest in 25% of the option shares on your first year anniversary date,
and then 1/48th for each month of continuous service thereafter.

 

		4.	Employment, Confidential Information and Invention
Assignment Agreement. Like all Company employees, you will be required, as a condition to your employment with the Company,
to sign the Company’s standard Employment, Confidential Information and Invention Assignment Agreement.

 

		5.	Period of Employment. Your employment with the
Company will be “at will,” meaning that either you or the Company will be entitled to terminate your employment at any
time and for any reason, with or without cause. Any contrary representations, which may have been made to you, are superseded
by this offer. This is the full and complete agreement between you and the Company on this term. Although your job duties, title,
compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at
will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer
of the Company.

 

     

     

    

 

Sandy Breber

March 07, 2019

Page 2

 

		6.	Withholding Taxes. All forms of compensation referred
to in this letter are subject to reduction to reflect applicable withholding and payroll taxes.

 

		7.	Entire Agreement. This letter and the subsequent
Confidential Information and Invention Assignment Agreement contain all of the terms of your employment with the Company and supersede
any prior understandings or agreements, whether oral or written, between you and the Company.

 

		8.	Amendment and Governing Law. This letter agreement
may not be amended or modified except by an express written agreement signed by you and a duly authorized officer of the Company.
The terms of this letter and the resolution of any disputes will be governed by California law. We hope that you find the foregoing
terms acceptable. You may indicate your agreement with these terms and accept this offer by signing and dating the enclosed duplicate
original of this letter and the enclosed Employment, Confidential Information and Invention Assignment Agreement and returning
both documents to me. As required by law, your employment with the Company is also contingent upon you providing legal proof of
your identity and authorization to work in the United States.

 

Notwithstanding the foregoing, your employment is also
subject to the following terms:

 

In addition, you will be eligible to
be considered for a performance bonus. Your target bonus will be equal to $82,500. The bonus (if any) will be awarded based
on the achievement of company and individual goals for the remainder of calendar 2019.

 

The Performance Bonus will be weighted as follows:

 

		●	25% contingent on company performance

 

		●	25% contingent on team performance

 

		●	50% contingent on individual performance

 

The Performance Bonus will be payable in two separate
increments:

 

		●	1/3 of your earned bonus will be paid following the end
of the Q2 in July 2019

 

		●	2/3 of your earned bonus will be paid following the end
of Q4 in January 2020

 

     

     

    

 

Sandy Breber

March 07, 2019

Page 3

 

Any bonus for the fiscal year in which your employment
begins will be prorated, based on the number of days you are employed by the Company during that fiscal year. Any bonus for a fiscal
year will be paid based on the above schedule, but only if you are still employed by the Company at the time of payment. The determinations
of the Company’s Board of Directors with respect to your bonus will be final and binding.

 

	Sincerely,	 
	 	 
	/s/ Manny Krakaris 	 
	Manny Krakaris	 
	 CEO	 
	Augmedix, Inc.	 
	 	 
	/s/ Sandy Breber 	 
	Sandy BreberExhibit 10.5

 

AUGMEDIX, INC.

1161
Mission Street, Suite 210

San
Francisco, Ca 94103

 

August
09, 2017

 

Matteo Marchetta

Via email to: [*]

 

Dear Matteo,

 

Augmedix, Inc. (the “Company”) is pleased to offer
you employment on the following terms:

 

		1.	Position and Start Date. Beginning August 25,
2017, you will serve in a full-time capacity as Chief Financial Officer. By signing this letter agreement, you represent and
warrant to the Company that you are under no contractual commitments inconsistent with your obligations to the Company.

 

		2.	Salary. You will be paid a salary at the initial
annual rate of $280,000, payable in Bi-weekly installments in accordance with the Company’s standard payroll practices for salaried
employees. This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time
to time.

 

		3.	Employment, Confidential Information and Invention
Assignment Agreement. Like all Company employees, you will be required, as a condition to your employment with the Company,
to sign the Company’s standard Employment, Confidential Information and Invention Assignment Agreement.

 

		4.	Period of Employment. Your employment with the
Company will be “at will,” meaning that either you or the Company will be entitled to terminate your employment at any
time and for any reason, with or without cause. Any contrary representations, which may have been made to you, are superseded
by this offer. This is the full and complete agreement between you and the Company on this term. Although your job duties, title,
compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at
will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer
of the Company.

 

		5.	Withholding Taxes. All forms of compensation referred
to in this letter are subject to reduction to reflect applicable withholding and payroll taxes.

 

		6.	Entire Agreement.
This letter and the subsequent Confidential Information and Invention Assignment Agreement contain all of the terms of your employment
with the Company and supersede any prior understandings or agreements, whether oral or written, between you and the Company.

 

     

     

    

 

Matteo Marchetta

August 09, 2017

Page 2

 

		7.	Amendment and Governing Law. This letter agreement
may not be amended or modified except by an express written agreement signed by you and a duly authorized officer of the Company.
The terms of this letter and the resolution of any disputes will be governed by California law. We hope that you find the foregoing
terms acceptable. You may indicate your agreement with these terms and accept this offer by signing and dating the enclosed duplicate
original of this letter and the enclosed Employment, Confidential Information and Invention Assignment Agreement and returning
both documents to me. As required by law, your employment with the Company is also contingent upon you providing legal proof of
your identity and authorization to work in the United States.

 

Notwithstanding the foregoing, your employment is also subject
to the following terms:

 

Stock Options. Subject to the approval of the Company’s
Board of Directors or its Compensation Committee, you will be granted an option to purchase shares of the Company’s Common Stock
for a total of 1.2% ownership stake (on a fully diluted basis, calculated on 9th August 2017 including the number of shares reserved
under the company’s employee stock option plan). The exercise price per share will be equal to the fair market value per share
on the date the option is granted or on your first day of employment, whichever is later. The option will be subject to the terms
and conditions applicable to options granted under the Company’s Employee Stock Plan. You will vest in 25% of the option shares
on your first year anniversary date, and then 1/48th for each month of continuous service thereafter. Full acceleration on double
trigger applies. The following options language will be included as part of your contract:

 

“100% double-trigger acceleration as follows:
If there is an Acquisition (as defined in the Plan) and if, during the period of time commencing ninety (90) days prior to the
consummation of such Acquisition and ending on the first anniversary of the consummation of such Acquisition, optionee’s employment
by the Company is terminated by the Company other than for Cause (as defined in the Plan), or is terminated by optionee for Good
Reason (as defined below), then 100% of the then unvested portion of the option shall accelerate effective as of immediately prior
to such termination, or in the case of a termination prior to consummation of an Acquisition, upon such Acquisition. “Good
Reason” means any of the following actions by the Company without optionee’s written consent: (a) a material reduction in
optionee’s duties or responsibilities that is inconsistent with optionee’s position, provided that a mere change of title alone
shall not constitute such a material reduction; (b) the requirement that optionee change his or her principal office to a facility
that increases optionee’s commute by more than forty (40) miles from optionee’s commute to the location at which optionee is employed
prior to such change, or (c) a material reduction in optionee’s annual base salary or a material reduction in optionee’s employee
benefits (e.g., medical, dental, insurance, short- and long-term disability insurance and 401(k) retirement plan benefits, collectively,
the “Employee Benefits”) to which optionee is entitled immediately prior to such reduction (other than (i) in connection
with a general decrease in the salary or Employee Benefits of all similarly situated employees and (ii) following an Acquisition,
to the extent necessary to make optionee’s salary or Employee Benefits commensurate with those other employees of the Company or
its successor entity or parent entity who are similarly situated with optionee following such Acquisition).”

 

     

     

    

 

Matteo Marchetta

August 09, 2017

Page 3

 

Severance. In case of an involuntary termination you
will be paid two months salary as severance.

 

Bonus
program. You will be eligible for a bonus program based on individual performance and company performance with a max payout that
will yield up to $70,000 on top of your base salary earnings. The guidelines of this program (e.g. target, institution date, etc.)
will be formed in collaboration with the executive team and will require Board approval.

 

Offer. This offer of employment is contingent upon the satisfactory
outcome of a personal background check, which may include professional references.

 

	Sincerely,	 
	 	 
	/s/ Ian Shakil	 
	Ian Shakil	 
	 CEO	 
	Augmedix, Inc.	 
	 	 
	/s/ Matteo Marchetta	 
	Matteo Marchetta

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]